Tackling Inflammation With Innovative Alzheimer Disease Treatments: Stanley H. Appel, MD
The director of the Ann Kimball and John W. Johnson Center for Cellular Therapeutics at Houston Methodist Hospital talked about the phase 2 study assessing low-dose COYA 301 in mild-to-moderate Alzheimer disease and the focus on inflammation in this patient population. [WATCH TIME: 5 minutes]
The Underlying Pathology of MS
Experts describe our current understanding of the pathology of multiple sclerosis (MS).
Informing Patient on Smouldering MS
Experts offer their experience on educating patients about smouldering multiple sclerosis (MS).
Looking Back on the Latest Advancements in Acute Migraine Treatment: Andrea S. Synowiec, DO, FAAN
The system vice chair for the department of neurology at Allegheny Health Network talked about the latest preventive and acute treatment options for patients with migraine as well as the progress of research in recent months. [WATCH TIME: 3 minutes]
Gene Therapy, Innovative Drugs, Surgical Techniques, and the Evolving Landscape of Epilepsy Care: Gregory Krauss, MD
The professor of neurology at Johns Hopkins University School of Medicine talked about the need for education to optimize treatment selection and the continually changing landscape of care for patients with epilepsy. [WATCH TIME: 5 minutes]
Balancing New Medications and Reducing Adverse Effects in Epilepsy Treatment: Louis Ferrari, RPh, MBA
The vice president of medical affairs at SK Life Science talked about findings from a new post-hoc analysis which highlighted the importance of strategically reducing concomitant medications to minimize adverse events of epilepsy treatment. [WATCH TIME: 5 minutes]
Greater Insights into Seizure Causes With Epilepsy Genetic Testing in Adults: Yi Li, MD, PhD
The clinical assistant professor of neurology at Stanford University talked about findings from a study on genetic testing in adults with epilepsy and the importance of access to genetic testing for this patient population. [WATCH TIME: 7 minutes]
Subgroups and Phenotypes of Myasthenia Gravis
Dr Neelam Goyal describes types of myasthenia gravis, its presentation, and differential diagnosis of myasthenia gravis.
Myasthenia Gravis and Underlying Pathophysiology
A neuromuscular disorder specialist, Dr Neelam Goyal discusses prevalence and pathophysiology of myasthenia gravis (MG).
Emphasizing Patient Conversations and Treatment Opportunities for Seizure Management: Danielle Becker, MD, MS, FAES
The division director of epilepsy and associate professor of neurology at The Ohio State University Wexner Medical Center talked about the impact of ongoing seizures in patients with drug-resistant epilepsy and the importance of education for emerging opportunities in epilepsy care. [WATCH TIME: 3 minutes]
Key Takeaways From ANNEXA-I Study
Dr Connolly highlights the cautious patient selection and the significance of reducing hematoma expansion for improved outcomes in cases of intracerebral hemorrhage (ICH) associated with the use of a reversal agent for factor Xa inhibitors.
BTKi Treatment Paradigm
Neurology experts discuss where BTKi’s fit in the multiple sclerosis treatment continuum.
BTKi Treatment: Clinical Measures
Experts provide insights about what clinical measures they look for when treating patients with BTKis for multiple sclerosis.
BTKi Effect on Chronic Active Lesions
Neurology experts discuss the potential effects of BTKi on chronic active lesions during multiple sclerosis therapies.
How Surgical Interventions Improve Survival Rate in Pediatric Epilepsy: Sandi K. Lam, MD, MBA
The division chief of pediatric neurosurgery at Ann & Robert H. Lurie Children's Hospital of Chicago talked about findings from a recently published study on long-term survival of pediatric patients with drug-resistant epilepsy which was presented at AES 2023. [WATCH TIME: 6 minutes]
Communicating With Patients About HD
Daniel Claassen, MD, MS, shares his approach to diagnosing patients with HD, as well as communicating with patients about the hereditary nature of the disease.
Overview of Huntington’s Disease (HD)
Daniel Claassen, MD, MS, provides an overview of the pathophysiology and genetic background of Huntington’s disease (HD), a neurodegenerative disorder.
The Persistent Challenge of Epilepsy Treatment Through the Ages: Louis Ferrari, RPh, MBA
The vice president of medical affairs at SK Life Science discussed how epilepsy remains a formidable challenge in the development of effective therapies to achieve seizure freedom. [WATCH TIME: 5 minutes]
Embracing New Approaches to Seizure Control Beyond Surgery: Gregory Krauss, MD
The professor of neurology at Johns Hopkins University School of Medicine discussed the traditional view of epilepsy treatment and how the paradigm has shifted to provide new treatments to achieve seizure freedom for drug-resistant patients. [WATCH TIME: 5 minutes]
Empowering Patient Voice in Epilepsy Treatment and Strategies for Seizure Freedom: Patrick Kwan, MD, PhD, FRCP
The professor of neurology in the department of neuroscience at Monash University discussed implementation strategies for treatment approaches to achieve seizure freedom in patients with epilepsy. [WATCH TIME: 5 minutes]
Phase 2 Trial of Alzheimer Psychosis Initiated, FDA Declines to Lift Hold on ENTR-601-44, Levetiracetam and Clobazam With Safety Warnings
Neurology News Network for the week ending December 1, 2023. [WATCH TIME: 4 minutes]
A Paradigm Shift in Preventing Drug-Resistant Epilepsy: Pavel Klein, MD
The director of the Mid-Atlantic Epilepsy & Sleep Center and adjunct associate professor of neurology at George Washington University discussed the advancements in epilepsy research, especially for drug-resistant epilepsy, to be presented at AES 2023. [WATCH TIME: 4 minutes]
Exploring the Hidden Burdens of Persistent Seizures for Patients: Danielle Becker, MD, MS, FAES
The division director of epilepsy and associate professor of neurology at The Ohio State University Wexner Medical Center discussed the profound repercussion of ongoing seizures for patients with epilepsy which is to be presented at AES 2023 in SK Life Science’s symposium. [WATCH TIME: 5 minutes]
Identifying and Classifying Multiple Sclerosis (MS): An Expert Discussion
Experts discuss the challenges of detecting progression in multiple sclerosis (MS), addressing the lack of available assessment tools but the importance of patient-reported signs and symptoms.
Role of Fluid Biomarkers and GFAP in Neurodegeneration: Charles Bernick, MD
The neurologist at Cleveland Clinic provided perspective on the reasons to study individuals exposed to repetitive head impacts and the lessons learned about monitoring glial fibrillary acidic protein over time. [WATCH TIME: 4 minutes]
Smouldering Multiple Sclerosis Introduction
Experts begin this series on smouldering multiple sclerosis (MS) highlighting our current understanding of pathophysiology, it’s prevalence, and how we may better detect it in the future.
Shining a Light on Movement Disorders, Advocating for Awareness and Access to Care: Andréa Merriam & Larry Gifford
The chief executive officer at Parkinson & Movement Disorder Alliance and the president at PD Avengers discussed the importance of awareness in movement disorders and the challenges that patients still face in getting access to treatments for improved quality of life. [WATCH TIME: 12 minutes
AI in Multiple Sclerosis: Expert Insights Into Limitations and Opportunities
Experts share insights on the latest innovations in multiple sclerosis research, in highlights from a recent State of the Science SummitTM, presented by Neurology Live®.
Evaluating Therapeutic Targets for Deep Brain Stimulation in Parkinson Disease: Alfonso Fasano, MD, PhD
The professor of neurology at the University of Toronto provided insight on several prominent targets in the brain for deep brain stimulation, including emerging ones that may not gain as much attention. [WATCH TIME: 3 minutes]
Eptinezumab’s Real-World Impact as Chronic Migraine Treatment: Amaal Starling, MD, FAHS, FAAN
The associate professor in the department of neurology at Mayo Clinic College of Medicine talked about findings from a real-world study assessing eptinezumab among patients with chronic migraine which was presented at the AHS Scottsdale Headache Symposium 2023. [WATCH TIME: 4 minutes]
2 Clarke Drive Cranbury, NJ 08512